MREO News and Press, Mereo BioPharma Group From 12/24/20

Gainers: [[ACY]] +39.4%. [[MREO]] +5.0%. [[SOAC]] +4.2%. [[GTHX]] +4.0%. [[STPK]] +3.4%.Losers: [[AIRT]] -23.1%. [[SCPS]] -9.4%. [[TRITW]] -6.8%. [[ID]] -6.0%. [[VET]] -4.9%. For further details see: ACY, MREO, AIRT and ID among after-hours movers

Gainers: CURO Group (CURO) +78%.Mereo BioPharma (MREO) +49%.Cyclo Therapeutics (CYTH) +42%.China Green Agriculture (CGA) +30%.Origin Agritech (SEED) +23%.Upstart (UPST) +22%.AgEagle Aerial Systems (UAVS) +22%.Elys Game Technology (ELYS) +22%.Organovo (ONVO) +21%.Aqua Metals (AQMS) +...

Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...

Can These 5 Penny Stocks Continue to Rally? Throughout the month of December, investors have seen a lot of positive sentiment with penny stocks . While trading these stocks has changed in 2020, the majority of the factors remain largely the same. This includes understanding the fund...

CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...

Gainers: [[MREO]] +37.1%. [[BW]] +9.1%. [[ABUS]] +6.1%. [[CLNY]] +5.1%. [[MVIS]] +4.4%.Losers: [[SCPS]] -22.7%. [[SCHL]] -13%. [[SCS]] -7.3%. [[AIR]] -6.8%. [[X]] -5.1%. For further details see: X, CLNY, MVIS and AIR among after-hours movers

Mereo BioPharma (MREO) jumps 18% after hours, after announcing a license and collaboration agreement with Ultragenyx Pharmaceutical (RARE) for setrusumab,  a monoclonal antibody, for osteogenesis imperfecta ((OI)), a rare genetic disorder characterized by fr...

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest o...

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest o...

LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today provided a further update...